stockportfolio.pro
LLY vs MRK: Which Stock Is the Better Buy?
Eli Lilly and Company and Merck & Co., Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — LLY vs MRK, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Eli Lilly and Company (LLY) | Merck & Co., Inc. (MRK) | |
|---|---|---|
| Market cap | $1.08T | $320.0B |
| Revenue (latest FY) | $65.18B | $65.01B |
| Net income (latest FY) | $20.64B | $18.25B |
| Revenue growth (5y CAGR) | 21.6% | 9.4% |
| Net margin | 31.7% | 28.1% |
| Return on equity | 77.8% | 34.7% |
| P/E ratio | 43.1 | 36.5 |
| Dividend yield | 0.6% | 2.6% |
| Profitable years (of last 10) | 9 | 10 |
| Positive free cash flow | — | Yes |
See the full LLY vs MRK breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open LLY's full financials → Open MRK's full financials →Frequently asked questions
Which is bigger, LLY or MRK?
Eli Lilly and Company is larger by market capitalization — $1.08T versus $320.0B.
Which grows faster, LLY or MRK?
Over the last five fiscal years, Eli Lilly and Company grew revenue faster — 21.6%/yr versus 9.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.